Pharmaceutical Technology
Researchers at the University of Toronto have launched two pharma start-ups dedicated to pursuing new treatments through an open-science model of drug development. The firms' strategy encourages accelerated drug discovery and development by forgoing profits and patent protection in favor of public data-sharing and broader collaboration. Could the pharma industry learn something from this open approach to drug development?